We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$2.21M
Cap. Flow
-$39.8M
Cap. Flow %
-1.28%
Top 10 Hldgs %
35.29%
Holding
188
New
16
Increased
26
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.7M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$32.2M
3
MRNA icon
Moderna
MRNA
+$25.5M
4
DHR icon
Danaher
DHR
+$16.7M
5
RMD icon
ResMed
RMD
+$15.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.3M
2
EXAS
Exact Sciences
EXAS
+$21.5M
3
CTLT
CATALENT, INC.
CTLT
+$19.2M
4
XRAY icon
Dentsply Sirona
XRAY
+$17.1M
5
CI icon
Cigna
CI
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Real Estate 2.82%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
26
Cigna
CI
$76.1B
$32.9M 1.06%
143,423
-78,317
-35% -$16.6M
BIIB icon
27
Biogen
BIIB
$30.7B
$32.5M 1.05%
135,639
-98,214
-42% -$25.3M
HUM icon
28
Humana
HUM
$44B
$32.3M 1.04%
69,660
+16,525
+31% +$7.31M
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$27.5B
$32.2M 1.04%
189,695
– –
MOH icon
30
Molina Healthcare
MOH
$10.2B
$31.3M 1.01%
98,325
+14,700
+18% +$4.37M
ICLR icon
31
Icon
ICLR
$12.8B
$30.6M 0.99%
98,871
– –
ZTS icon
32
Zoetis
ZTS
$31.9B
$29.9M 0.96%
122,497
-20,100
-14% -$4.4M
HCA icon
33
HCA Healthcare
HCA
$85.7B
$28.8M 0.93%
111,961
– –
SRPT icon
34
Sarepta Therapeutics
SRPT
$1.64B
$28.4M 0.92%
315,897
-110,617
-26% -$9.46M
IQV icon
35
IQVIA
IQV
$39.1B
$27.7M 0.89%
98,154
+21,510
+28% +$5.58M
CRL icon
36
Charles River Laboratories
CRL
$11.3B
$23.4M 0.75%
61,990
-16,494
-21% -$6.41M
BNTX icon
37
BioNTech
BNTX
$23.5B
$23.3M 0.75%
90,242
+9,485
+12% +$2.6M
EW icon
38
Edwards Lifesciences
EW
$50B
$23M 0.74%
177,188
-17,442
-9% -$2.03M
BSX icon
39
Boston Scientific
BSX
$68.4B
$22.8M 0.73%
536,042
+350,111
+188% +$14.7M
DXCM icon
40
DexCom
DXCM
$28.8B
$22.5M 0.72%
167,724
-4,196
-2% -$603K
UTHR icon
41
United Therapeutics
UTHR
$26.2B
$22M 0.71%
101,737
-43,203
-30% -$8.48M
ISRG icon
42
Intuitive Surgical
ISRG
$126B
$20.7M 0.67%
57,606
-2,400
-4% -$826K
RLYB icon
43
Rallybio
RLYB
$85.3M
$20.4M 0.66%
288,584
– –
RMD icon
44
ResMed
RMD
$30.3B
$19.4M 0.63%
74,599
+60,410
+426% +$15.7M
ZBH icon
45
Zimmer Biomet
ZBH
$18.4B
$18M 0.58%
146,305
-83,079
-36% -$10.9M
WELL icon
46
Welltower
WELL
$170B
$17.4M 0.56%
203,083
– –
ONC
47
BeOne Medicines Ltd
ONC
$33.4B
$17.3M 0.56%
63,772
– –
ARNA
48
DELISTED
Arena Pharmaceuticals Inc
ARNA
$16.4M 0.53%
175,976
+92,347
+110% +$6.08M
XLV icon
49
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
$16M 0.51%
113,230
-19,600
-15% -$2.6M
CVS icon
50
CVS Health
CVS
$134B
$15.2M 0.49%
147,453
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Tekla Capital Management held 188 positions worth $3.11B, up 0.07% from $3.11B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q4 2021 filing shows 16 new, 26 increased, 40 reduced and 17 closed positions. Its largest new stake was AMN Healthcare: 61,201 shares worth $7.49M. The largest sale was Biogen, an estimated $25.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2021 buy was AMN Healthcare: 61,201 shares worth $7.49M.
  • Tekla Capital Management added most to Pfizer in Q4 2021, an estimated $35.7M increase.
  • Tekla Capital Management's biggest Q4 2021 reduction was Biogen, cutting an estimated $25.3M.
  • Tekla Capital Management fully exited Exact Sciences in Q4 2021, selling an estimated $21.5M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $3.11B portfolio in Q4 2021.
  • Tekla Capital Management opened 16 new positions and closed 17 in Q4 2021.
  • Tekla Capital Management's portfolio value rose 0.07% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.